TOTH A ERNEST JR 4

What Happened
Ernest Toth, Chief Financial Officer of Aquestive Therapeutics (AQST), reported a sale and new awards. On 2026-03-10 he sold 58,254 shares in an open-market transaction for total proceeds of about $243,094 (weighted-average price $4.17). On 2026-03-09 he was granted 95,000 restricted shares and 70,000 derivative awards (total 165,000) at $0.00 consideration; these awards carry multi-year vesting schedules.

Key Details

• Transaction dates: awards on 2026-03-09; sale on 2026-03-10. Form 4 filed 2026-03-11 (timely filing).
• Sale details: 58,254 shares disposed; weighted-average sale price $4.17; execution prices ranged $4.17–$4.32 (multiple trades); proceeds ≈ $243,094. (Footnote F3.)
• Grants: 95,000 restricted stock units/awards (F1) and 70,000 derivative awards (F4) granted at $0.00; both vest in three annual installments (25% / 25% / 50%).
• Tax-withholding: the sale represents shares sold to cover tax withholding associated with vesting ("sell to cover"), not a discretionary stock-sale decision by the CFO (Footnote F2).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: appears timely (filed within the Form 4 reporting window).

Context
"Sell to cover" transactions are routine when restricted awards vest and taxes are due; such mandated sales do not necessarily indicate a change in the insider's view of the company. The grants are time‑based and will vest over three years per the footnotes, so their value depends on future share price and vesting.